[go: up one dir, main page]

ES2116447T3 - Una composicion farmaceutica que contiene un sistema definido de lipidos. - Google Patents

Una composicion farmaceutica que contiene un sistema definido de lipidos.

Info

Publication number
ES2116447T3
ES2116447T3 ES93908233T ES93908233T ES2116447T3 ES 2116447 T3 ES2116447 T3 ES 2116447T3 ES 93908233 T ES93908233 T ES 93908233T ES 93908233 T ES93908233 T ES 93908233T ES 2116447 T3 ES2116447 T3 ES 2116447T3
Authority
ES
Spain
Prior art keywords
pharmaceutical
pharmaceutical composition
composition containing
lipid system
defined lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908233T
Other languages
English (en)
Inventor
Hakan Nyqvist
Monica Einarsson
Christer Mattsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2116447T3 publication Critical patent/ES2116447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN SISTEMA LIPIDO DEFINIDO DE AL MENOS DOS COMPONENTES LIPIDOS DONDE AL MENOS UNO DE LOS COMPONENTES LIPIDOS ES ANFIFATICO O POLAR Y OTRO ES NO POLAR EN DONDE EL COMPUESTO FARMACEUTICAMENTE ACTIVO ES UNA HEPARINA O UN FRAGMENTO DE LA MISMA. EN LAS COMPOSICIONES TAMBIEN SE INCLUYE UN SOLVENTE QUE CONTIENE AGUA EN UNA CANTIDAD TAL QUE HAYA PARTICULAS DE LIPIDOS DISCRETAS PRESENTES Y DICHAS COMPOSICIONES SE PUEDEN ADAPTAR A VARIAS FORMAS DE ADMINISTRACION TALES COMO RECTAL, ORAL, BUCAL, TRANSDERMICA, ETC.
ES93908233T 1992-03-27 1993-03-26 Una composicion farmaceutica que contiene un sistema definido de lipidos. Expired - Lifetime ES2116447T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9200951A SE9200951D0 (sv) 1992-03-27 1992-03-27 Pharmaceutical composition containing a defined lipid system

Publications (1)

Publication Number Publication Date
ES2116447T3 true ES2116447T3 (es) 1998-07-16

Family

ID=20385757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908233T Expired - Lifetime ES2116447T3 (es) 1992-03-27 1993-03-26 Una composicion farmaceutica que contiene un sistema definido de lipidos.

Country Status (23)

Country Link
US (1) US5626869A (es)
EP (1) EP0591492B1 (es)
JP (1) JP3577312B2 (es)
KR (1) KR100243921B1 (es)
AT (1) ATE165971T1 (es)
AU (1) AU3912493A (es)
CA (1) CA2102494C (es)
CZ (1) CZ285672B6 (es)
DE (1) DE69318503T2 (es)
DK (1) DK0591492T3 (es)
ES (1) ES2116447T3 (es)
FI (1) FI110842B (es)
HU (1) HU219240B (es)
IL (1) IL105017A (es)
MX (1) MX9301716A (es)
NO (1) NO305537B1 (es)
NZ (1) NZ251488A (es)
PL (1) PL172896B1 (es)
RU (1) RU2128505C1 (es)
SE (1) SE9200951D0 (es)
SK (1) SK280494B6 (es)
WO (1) WO1993019737A1 (es)
ZA (1) ZA931470B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
ATE252889T1 (de) 1998-08-19 2003-11-15 Skyepharma Canada Inc Injizierbare wässerige propofoldispersionen
AU770803B2 (en) 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU5409699A (en) 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
WO2001010411A2 (de) * 1999-08-06 2001-02-15 Max-Delbrück-Centrum für Molekulare Medizin Implantierbares wirkstoffdepot
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
FR2803202B1 (fr) * 2000-01-03 2004-04-16 Capsulis Compositions pharmaceutiques destinees a une adminstration par voie orale
SE0000730D0 (sv) * 2000-03-06 2000-03-06 Scotia Holdings Plc Lipid carrier
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
US9308220B2 (en) * 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
SE0201922D0 (sv) 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
WO2005094785A2 (en) * 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP3403647A1 (en) 2009-12-01 2018-11-21 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP2512448B1 (en) 2009-12-18 2016-07-06 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
US9303263B2 (en) 2013-03-01 2016-04-05 Vivonics, Inc. Aptamers that bind CD271
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
CA2904151C (en) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
MX2016005238A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
US20160060655A1 (en) 2014-05-30 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections
CN106659731A (zh) 2014-05-30 2017-05-10 夏尔人类遗传性治疗公司 用于递送核酸的可生物降解脂质
UA121863C2 (uk) 2014-06-24 2020-08-10 Транслейт Байо, Інк. Стереохімічно збагачені композиції для доставки нуклеїнових кислот
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
CA3000155A1 (en) 2015-05-29 2016-12-08 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8219012A0 (it) * 1982-01-06 1982-01-06 Ausonia Farma Srl Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
JPS607934A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
AU604288B2 (en) * 1987-01-26 1990-12-13 Vestar, Inc. Phospholipid delivery vehicle for aqueous-insoluble active ingredients
SE9003100D0 (sv) * 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system

Also Published As

Publication number Publication date
MX9301716A (es) 1994-01-31
EP0591492B1 (en) 1998-05-13
DE69318503D1 (de) 1998-06-18
HU219240B (en) 2001-03-28
ZA931470B (en) 1993-09-23
WO1993019737A1 (en) 1993-10-14
CA2102494C (en) 2008-03-18
US5626869A (en) 1997-05-06
PL172896B1 (pl) 1997-12-31
CZ285672B6 (cs) 1999-10-13
DK0591492T3 (da) 1999-02-15
SK132293A3 (en) 1994-07-06
NO305537B1 (no) 1999-06-21
KR100243921B1 (ko) 2000-03-02
DE69318503T2 (de) 1998-11-05
AU3912493A (en) 1993-11-08
ATE165971T1 (de) 1998-05-15
NO934284D0 (no) 1993-11-26
CA2102494A1 (en) 1993-09-28
NO934284L (no) 1993-11-26
HU9303357D0 (en) 1994-03-28
EP0591492A1 (en) 1994-04-13
FI110842B (fi) 2003-04-15
JP3577312B2 (ja) 2004-10-13
FI935273L (fi) 1993-11-26
IL105017A0 (en) 1993-07-08
CZ247793A3 (en) 1994-07-13
NZ251488A (en) 1996-03-26
IL105017A (en) 1999-12-22
SK280494B6 (sk) 2000-03-13
HUT70405A (en) 1995-10-30
SE9200951D0 (sv) 1992-03-27
FI935273A0 (fi) 1993-11-26
JPH06508155A (ja) 1994-09-14
RU2128505C1 (ru) 1999-04-10

Similar Documents

Publication Publication Date Title
ES2116447T3 (es) Una composicion farmaceutica que contiene un sistema definido de lipidos.
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
ES2191862T3 (es) Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18.
PA8509801A1 (es) Compuestos antibioticos de azalida
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
SE8505112D0 (sv) Novel pharmacological compounds
CR5908A (es) Composiciones cosmeticas con dbs y siliconas funcionalizadas
DE3381396D1 (de) Formulierung nicht irritierender ophthalmischer waesseriger zusammensetzungen fuer okular-therapeutische mittel.
AR019790A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
FI892454A0 (fi) Nya bensimidazolderivat, foerfarande foer framstaellning av desamma och farmaceutisk komposition innehaollande desamma.
DE69415223D1 (de) Feste, transparente Seifenzusammensetzung auf Basis von Fettsäuresalzen, enthaltend Isoprenglykol
BR0111678A (pt) Composições medicinais contendo derivados de propenona
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
SE8600658D0 (sv) Novel composition of matter
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
SE8006550L (sv) Farmakologisk komposition, samt sett for dess framstellning
BRPI0510694A (pt) composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole
ES2095431T3 (es) N-(isoquinolein-5-il)-sulfonil-azacicloalcanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
SE7901203L (sv) O-substituerade oximderivat av 7-amino-tiazolyl-acetamido-cefalosporansyra, sett for framstellning och anvendning derav som lekemedel samt farmaceutiska kompositioner innehallande dessa foreningar
AR012972A1 (es) Forma farmaceutica para la administracion de paclitaxel, proceso para la preparacion de una composicion de paclitaxel lista para usar y uso de estacomposicion
ES2162986T3 (es) Derivados de mercapto-alcanoil-dipeptidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
BR0308475A (pt) Formulação de eplerenona estável na armazenagem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 591492

Country of ref document: ES